Zr-DFO-APAC

Phase 1Small molecule

AAplagon Oy

Zr-DFO-APAC is one of 4 small molecule programs targeting Anticoagulant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnticoagulantRecruiting

AnticoagulantPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Anticoagulant

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

13 2

Lovenox

Sanofi

Phase 1

3 3

VMX-C001

VVarmX B.V.

Phase 1

2 4

Zr-DFO-APAC

AAplagon Oy

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anticoagulant1 trial

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

Recruiting·AAplagon Oy·Phase 1·NCT06204237·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zr-DFO-APAC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zr-DFO-APAC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zr-DFO-APAC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aplagon Oy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAplagon Oy

Zr-DFO-APAC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anticoagulant1 trial

References

Drug Info

Quick Facts

Related News